The LATAM Mastercourse 2026, organized by the Princess Máxima Center and the Fundación Pérez Scremini, will once again bring together international and regional leaders in pediatric oncology in Montevideo.

​

In its third edition, the course will focus on Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy, two of the most innovative strategies in the treatment of children, adolescents, and young adults with cancer.

Over five intensive days, experts from world-renowned centers such as the Princess Máxima Center (The Netherlands), Hospital Sant Joan de Déu (Barcelona, Spain), Memorial Sloan Kettering Cancer Center (United States), , the Hospital Austral (Argentina), GRAACC (Brazil), together with leading Latin American specialists, will share their knowledge and experiences, with a program tailored to the realities of the region.

With limited availability, this event offers a unique opportunity to access cutting-edge education, scientific exchange, and international networking.

​

Participants will explore key aspects of allogeneic stem cell transplantation (HSCT) and CAR-T cell therapy, including:

• Indications and timing of HSCT for ALL, AML, lymphomas, bone marrow failure, and immunodeficiencies.

• Conditioning regimens: donor sources (matched sibling, unrelated, haploidentical, cord blood) and intensity strategies.

• Supportive care: central lines, mucositis, antimicrobial prophylaxis, nutrition, and pain management.

• Acute and chronic complications: graft-versus-host disease (GvHD), sinusoidal obstruction syndrome (VOD/SOS), and infection management.

• Survivorship and late effects: endocrine, cardiopulmonary, and neurocognitive outcomes, fertility, and secondary tumors.

• Psychosocial and family-centered care: schooling, coping, and transition into adult care.

• CAR-T therapy: patient eligibility, manufacturing process, infusion monitoring, CRS and ICANS management, ICU support, and long-term follow-up.

• Future directions and access in Latin America, including a regional panel on how to make CAR-T therapy available in the region.